Krka d. d Past Earnings Performance
Past criteria checks 2/6
Krka d. d has been growing earnings at an average annual rate of 10.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 5.2% per year. Krka d. d's return on equity is 14.4%, and it has net margins of 17.4%.
Key information
10.3%
Earnings growth rate
10.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 29.4% |
| Revenue growth rate | 5.2% |
| Return on equity | 14.4% |
| Net Margin | 17.4% |
| Next Earnings Update | 16 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Krka d. d makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,806 | 314 | 455 | 179 |
| 30 Sep 23 | 1,816 | 298 | 435 | 170 |
| 30 Jun 23 | 1,780 | 298 | 447 | 167 |
| 31 Mar 23 | 1,743 | 362 | 454 | 165 |
| 31 Dec 22 | 1,717 | 363 | 440 | 163 |
| 30 Sep 22 | 1,631 | 369 | 440 | 161 |
| 30 Jun 22 | 1,615 | 367 | 420 | 160 |
| 31 Mar 22 | 1,602 | 313 | 401 | 157 |
| 31 Dec 21 | 1,566 | 309 | 393 | 155 |
| 30 Sep 21 | 1,551 | 320 | 369 | 154 |
| 30 Jun 21 | 1,540 | 308 | 369 | 155 |
| 31 Mar 21 | 1,468 | 292 | 365 | 155 |
| 31 Dec 20 | 1,535 | 291 | 378 | 153 |
| 30 Sep 20 | 1,563 | 284 | 407 | 154 |
| 30 Jun 20 | 1,536 | 267 | 422 | 152 |
| 31 Mar 20 | 1,578 | 261 | 431 | 154 |
| 31 Dec 19 | 1,493 | 246 | 434 | 152 |
| 30 Sep 19 | 1,451 | 226 | 441 | 146 |
| 30 Jun 19 | 1,414 | 213 | 427 | 143 |
| 31 Mar 19 | 1,372 | 196 | 427 | 136 |
| 31 Dec 18 | 1,332 | 175 | 420 | 131 |
| 30 Sep 18 | 1,310 | 163 | 419 | 128 |
| 30 Jun 18 | 1,291 | 163 | 413 | 126 |
| 31 Mar 18 | 1,283 | 159 | 411 | 126 |
| 31 Dec 17 | 1,266 | 153 | 414 | 126 |
| 30 Sep 17 | 1,250 | 138 | 410 | 126 |
| 30 Jun 17 | 1,226 | 130 | 405 | 121 |
| 31 Mar 17 | 1,195 | 111 | 408 | 120 |
| 31 Dec 16 | 1,174 | 108 | 394 | 118 |
| 30 Sep 16 | 1,154 | 105 | 389 | 116 |
| 30 Jun 16 | 1,169 | 116 | 387 | 118 |
| 31 Mar 16 | 1,176 | 143 | 380 | 117 |
| 31 Dec 15 | 1,165 | 158 | 387 | 115 |
| 30 Sep 15 | 1,197 | 172 | 405 | 114 |
| 30 Jun 15 | 1,192 | 172 | 406 | 111 |
| 31 Mar 15 | 1,183 | 179 | 413 | 111 |
| 31 Dec 14 | 1,192 | 166 | 407 | 108 |
| 30 Sep 14 | 1,201 | 175 | 390 | 99 |
| 30 Jun 14 | 1,203 | 179 | 391 | 99 |
| 31 Mar 14 | 1,204 | 164 | 389 | 98 |
| 31 Dec 13 | 1,201 | 173 | 393 | 97 |
| 30 Sep 13 | 1,187 | 173 | 394 | 105 |
| 30 Jun 13 | 1,175 | 170 | 401 | 104 |
Quality Earnings: KRK has high quality earnings.
Growing Profit Margin: KRK's current net profit margins (17.4%) are lower than last year (21.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRK's earnings have grown by 10.3% per year over the past 5 years.
Accelerating Growth: KRK's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: KRK had negative earnings growth (-13.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: KRK's Return on Equity (14.4%) is considered low.